Mets reliever Jenrry Mejia, who was serving his second suspension for PED use, was nailed a third time Friday and with it became the first player to receive a lifetime ban. This time, his drug of poor choice was Boldenone.
Technically, it’s not lifetime because Mejia can apply for reinstatement in one year. It’s probably a given the Mets aren’t going to give him another chance.
“We were deeply disappointed to hear that Jenrry has again violated Major League Baseball’s Joint Drug Prevention and Treatment Program,” the Mets said in a statement. “We fully support MLB’s policy toward eliminating performance enhancing substances from the sport. As per the Joint Drug Program, we will have no further comment on this suspension.”
Mejia’s first suspension was for 80 games and came last April when he tested positive for Stanozolol, which created the opportunity for Jeurys Familia to become the closer last year. While serving that suspension he tested positive for Stanozolol and Boldenone. That got him 162 games.
Even so, because of their vulnerability in the bullpen the Mets re-signed the 26-year-old Mejia in December. They thought it was a good gamble because he would get a prorated portion of his salary, which would come at less than a $1 million.
Believing they would have Mejia back in July, the Mets opted not to bring back dependable reliever Carlos Torres, who recently signed with Atlanta.